Show simple item record

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.

dc.contributor.authorWilson, G R
dc.contributor.authorCramer, Angela
dc.contributor.authorWelman, Arkadiusz
dc.contributor.authorKnox, W Fiona
dc.contributor.authorSwindell, Ric
dc.contributor.authorKawakatsu, H
dc.contributor.authorClarke, Robert B
dc.contributor.authorDive, Caroline
dc.contributor.authorBundred, Nigel J
dc.date.accessioned2009-07-07T15:55:07Z
dc.date.available2009-07-07T15:55:07Z
dc.date.issued2006-11-20
dc.identifier.citationActivated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. 2006, 95 (10):1410-4 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid17060931
dc.identifier.doi10.1038/sj.bjc.6603444
dc.identifier.urihttp://hdl.handle.net/10541/72839
dc.description.abstractOverexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial cancers including breast cancer. c-Src activity in 'pure' ductal carcinoma in situ (DCIS) was measured to assess whether this predicts recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with lower recurrence-free survival at 5 years (P=0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Recurrenceen
dc.subjectCancer Stagingen
dc.subjectTumour Markersen
dc.subject.meshBreast Neoplasms
dc.subject.meshCarcinoma, Ductal, Breast
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating
dc.subject.meshCell Proliferation
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasm Staging
dc.subject.meshPredictive Value of Tests
dc.subject.meshProto-Oncogene Proteins pp60(c-src)
dc.subject.meshReceptor, erbB-2
dc.subject.meshTumor Markers, Biological
dc.titleActivated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.en
dc.typeArticleen
dc.contributor.departmentDepartment of Academic Surgery, Research and Education Building 2nd Floor, South Manchester University Hospital, Wythenshawe, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractOverexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial cancers including breast cancer. c-Src activity in 'pure' ductal carcinoma in situ (DCIS) was measured to assess whether this predicts recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with lower recurrence-free survival at 5 years (P=0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.


This item appears in the following Collection(s)

Show simple item record